Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: ARCHIVE

ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscienceARCHIVE
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscienceARCHIVE
ARCHIVE: GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
GEN Biotechnology
sciencepublicationARCHIVE
ARCHIVE: GEN Biotechnology: Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space (cover story)April 17, 2025
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscienceARCHIVE
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscienceARCHIVE
ARCHIVE: BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial Officer
investorpress clippingsARCHIVEperriman
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial OfficerApril 3, 2025
ARCHIVE: Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025
investorARCHIVE
ARCHIVE: Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025April 3, 2025
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideoARCHIVEperriman
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
ARCHIVE: eXoZymes Provides Fourth Quarter and Full Year 2024 Update
press releaseinvestorARCHIVE
ARCHIVE: eXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025
ARCHIVE: Chemical Engineering: Enzyme engineering breaks out of the cell
press clippingsscienceARCHIVE
ARCHIVE: Chemical Engineering: Enzyme engineering breaks out of the cellApril 1, 2025
Previous page
Page 1 of 6
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark